Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-114889
Filing Date
2025-05-07
Accepted
2025-05-07 16:06:08
Documents
94
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q d907688d10q.htm   iXBRL 10-Q 1895049
2 EX-31.1 d907688dex311.htm EX-31.1 10358
3 EX-31.2 d907688dex312.htm EX-31.2 10343
4 EX-32 d907688dex32.htm EX-32 4331
  Complete submission text file 0001193125-25-114889.txt   10851461

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA teva-20250331.xsd EX-101.SCH 93682
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE teva-20250331_cal.xml EX-101.CAL 48379
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE teva-20250331_def.xml EX-101.DEF 572053
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE teva-20250331_lab.xml EX-101.LAB 625379
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE teva-20250331_pre.xml EX-101.PRE 608663
97 EXTRACTED XBRL INSTANCE DOCUMENT d907688d10q_htm.xml XML 1996005
Mailing Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020
Business Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020 972 (3) 914-8213
TEVA PHARMACEUTICAL INDUSTRIES LTD (Filer) CIK: 0000818686 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-16174 | Film No.: 25921298
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)